According to the newest clinical trial, Nicotinamide mononucleotide (NMN) reduces the time it takes to fall asleep and increases deep sleep in humans between ages 45 and 75 years.
Table of Contents
Human Age and Insomnia
Sleep difficulties in the elderly are often mistakenly assumed to be a natural aspect of aging. The most prevalent sleep problem, insomnia, is a subjective description of not getting enough or restorative sleep despite having the chance to do so. This deterioration affects not only the rapid eye movement (REM) stage of sleep but also the other stages of sleep that range from light to deep. With aging, the time spent in REM and deep sleep stages decreases, and the deepest sleep stage even disappears after the age of 60. Given that sleep plays a vital role in immune function, cognitive performance, and metabolism, the reduction in sleep quality due to aging can contribute to various age-related diseases.
Fighting Insomnia with NMN
The newest paper has published a study in the American Journal of Translational Medicine that suggests taking NMN may enhance sleep quality, as assessed by the PSQI sleep questionnaire. The research team also observed that the administration of NMN significantly reduced the time taken to fall asleep. Using smart band data obtained from the wrist, researchers found that NMN intake increased the duration of both REM and deep sleep stages. These findings imply that taking NMN may help to counteract age-related declines in sleep quality.
During the 12-week clinical trial, 58 individuals aged 45–75 years received treatment with NMN supplementation. To monitor and compare NMN’s impact on insomnia in middle-aged and elderly persons, they were randomly separated into NMN and control groups:
- NMN group: consumed 2 x 300 mg NMN capsules daily at lunchtime.
- The control group: consumed 2 x 300 mg placebo capsules (the main ingredient was edible starch) daily at lunchtime.
Each participant received a smart band connected to the Huawei Sports Health App to wear before bed. The band collected subjects’ sleep-related data such as daily bedtime, deep/light sleep ratio, REM, total sleep duration, and night waking time frequency. One week before the start of the experiment, all individuals received sleep health education and information on the procedures and requirements for submitting associated data. During the trial, they were not allowed to consume any alcohol, bitter tea, or other sleep-inducing liquids.
These are what they found:
- After the third week of treatment, the sleep duration and REM sleep ratio changed. By the sixth week, there was a considerable change in the ratios of deep and light sleep.
- The ratio of light sleep to awake time dropped. The ratios of deep and REM sleep, however, rose.
- After taking NMN, there are improvements in sleep duration, deep sleep ratio, and REM sleep ratios, while the light sleep ratio and waking frequency are reduced significantly.
- Between the NMN and control groups, there were significant differences in total PSQI values. The effectiveness of the NMN group was 65.52% – significantly greater than that of the control group.
In conclusion, the clinical results suggest that NMN (nicotinamide mononucleotide) supplementation can improve insomnia in middle-aged and older adults. NMN can positively impact sleep quality and duration, likely through its role in promoting the production of NAD+ and enhancing mitochondrial function.
Overall, NMN holds promise as a safe and effective natural intervention for those experiencing insomnia, and continued investigation into its potential benefits is warranted.
- Clinical observation of the effect of nicotinamide mononucleotide on the improvement of insomnia in middle-aged and old adults.
Subscribe to our newsletter (down below) for the newest scientific innovation, useful information, and effective tips for maintaining a healthy lifestyle.